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Abstract 
Purpose: To evaluate the prevalence of patients suffering from registered chronic disease list (CDL) 
conditions in a section of the South African private health sector from 2008 - 2012. 
Methods: This study was a retrospective analysis of the medicine claims database of a nationally 
(South African) representative Pharmacy Benefit Management (PBM) company data between 2008 and 
2012. Statistical analysis was used to analyse the data. Descriptive analysis was performed to calculate 
the prevalence of CDL conditions for the entire population, and stratified by age and gender. However, 
MIXED linear modelling was used to determine changes in the average number of CDL conditions per 
patient, adjusted for age and gender from 2008 - 2012. 
Results: An increase of 0.20 in chronic diseases was observed from 2008 - 2012 in patients having any 
CDL condition, with an average of 1.57 (1.57 - 1.58, 95 % CI) co-morbid CDL conditions in 2008 and 
1.77 (1.77 - 1.78, 95 % CI) in 2012. This increase in average number of CDL conditions per patient 
between 2008 and 2012 was statistically significant (p < 0.05), but with no large practical significance (d 
< 0.8). 
Conclusion: Prevalence of patients with CDL conditions along with risk of co-morbidity has been 
increasing with time in the private health sector of South Africa. Risk of increased co-morbidity with age 
and among different genders was prevalent. 
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Chronic non-communicable diseases (NCDs) 
such as diabetes, cardiovascular disease (CVD) 
and cancers pose a major public health threat 
worldwide. According to an estimate by WHO by 
2020, one-third of the global burden of disease 
will be attributable to chronic diseases [1]. Nearly 
one-third and 44 % of the deaths before age 60 
are due to chronic diseases in middle-income 
and low income countries, respectively. Various 
risk factors including unhealthy diets, physical 
inactivity, alcohol consumption, poor knowledge 
of health workers, low quality services and lack 
of access to medicines have been identified 
towards contribution of burden of chronic 
diseases [2]. This rise of burden of chronic 
diseases in turn has led to high costs of illness 
and potentially significant productivity losses [3]. 
 
The burden of non-communicable diseases as 
well as multi-morbidity, the co-existence of more 
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than one chronic condition in one person, is 
particularly rising in Africa. According to the study 
conducted by The Global Burden of Disease, HIV 
ranks first, TB fourth, cerebrovascular disease 
seventh, diabetes eighth while non-
communicable diseases contribute to fifty 
percent causes of morbidity in South Africa [4]. 
An estimated increase from 11 to 13 % and 3.2 
to 4.0 % since 2009 to 2025, for CDL conditions 
and multi-morbidity is anticipated [4]. The current 
situation of increased burden of chronic diseases 
is a major challenge to existing models of 
healthcare delivery systems in South Africa. 
Thus, it is important to recognise such illnesses 
and strategize appropriately to address them at 
individual patient care level [5].  
 
To address this dilemma, the South African 
Council for Medical Schemes formulated a 
chronic disease list (CDL) including the most 
common, life-threatening diseases. These 
conditions fall under a larger group, called 
prescribed minimum benefits, defined as a set of 
benefits to ensure that all medical scheme 
members have access to certain minimum health 
services; regardless of the benefit option they 
have selected [6,7]. This has created a positive 
impact on prescribing practices carried in private 
healthcare facilities. But, still limited data exists 
on assessing the prevalence of these particular 
combinations or clusters of chronic conditions, as 
most of the studies conducted so far in South 
Africa have been focused on comorbidities of a 
specific disease. 
 
Thus, the present study was designed to 
evaluate the prevalence of patients suffering 
from registered chronic disease list (CDL) 
conditions in a section of the South African 




This study was a retrospective analysis of the 
medicine claims database of a nationally (South 
African) representative PBM company data 
between 2008 and 2012.Approval was obtained 
for the study from the appropriate Pharmacy 
Benefit Management companies (PBM) as well 
as from the Ethics Committee of the North-West 
University (Human, Potchefstroom campus) (no. 
NWU-0046-08-A5) to conduct this drug utilisation 
study. The PBM Company provides services to 
four capitation providers, thirty-two medical 
schemes and four sick benefit society funds. The 
medicine benefits of approximately 1.6 million 
beneficiaries are maintained annually by the 
PBM company. 
 
The data fields used in this study include: 
quantity of medication claimed, member gender, 
member date of birth, NAPPI code, ICD-10 code, 
diagnose code, active pharmacological 
ingredient of the medication, number of 
prescriptions dispensed containing medication 
used to treat CDL conditions and period in which 
the item was dispensed. The chronic conditions 
included in this paper are listed (Table 1). 
 
Table 1: South African chronic disease list (CDL) 
 
Addison’s disease Dysrhythmia 
Asthama EpilepsyI 
Bronchiectasis      Glaucoma                    
Cardiac failure   Haemophilia A 
Cardiomyopathy Haemophilia B 
Chronic obstructive pulmonary 
disease   
Hyperlipidemia 
Chronic renal disease              Hypertension 
Coronoary artery disease Hypothyrodisim 
Crohn’s disease    Multiple sclerosis    
Diabetes insipudus Parkinson’s disease    
Diabetes mellitus type I Rheumatoid arthritis    
Diabetes mellitus type II Schizophrenia 
Systemic lupus erythematosus Ulcerative colitis 
 
Analyses were performed on patient level. The 
prevalence of each condition was calculated by 
dividing the number of patients with the condition 
by the number of active patients. Statistical 
Analysis System®, SAS 9.3®and Statistical 
Package for the Social Sciences (IBM SPSS® 
22) were used to analyse the data. Descriptive 
analysis was performed for calculating the 
prevalence of CDL conditions for the entire 
population and stratified by age and gender. 
MIXED linear modelling was used to calculate 
average number of CDL conditions per patient 
for the influence of age and gender differences 
so that the same patients prevalent in 2008 
remained also prevalent in 2012. These also 
involved patients that have either entered or left 
the medical scheme for any reason or came into 
the medical scheme any time during the study 




Prevalence of patients with at least one CDL 
condition 
 
The total number of patients on the database 
were 974,497 patients in 2008, 1,307,528 in 
2009, 1,220,289 in 2010, 1,077,834 in 2011 and 
1,029,699 patients in 2012. Patients with at least 
one CDL condition represented 21.9 % (n = 214 
279) of the total number of patients on the 
database in 2008, and they increased to 26 % (n 
= 268 685) in 2012. The representation of female 
Rothmann et al 
Trop J Pharm Res, June 2016; 15(6): 1329  
 
patients with at least one CDL condition 
increased from 23.3 % (2008) to 26.9 % (2012) 
and those of male patients from 20.3 % (2008) to 
25.1 % (2012).There was an increase in the 
number of patients with CDL conditions across 
all age groups except for age group ≤ 12 year 
with a decrease from 2.9 % (2008) to 2.7 % 
(2012). The other age groups: 12 > age ≤ 50 
years increased from 9.4 % (2008) to 10.7 % 
(2012); 50 > age ≤ 60 years increase from 33.6 
% (2008) to 40.1 % (2012); 60 > age ≤ 70 years 
increased from 57.1 % (2008) to 65 % (2012) 
and age > 70 years  from 71.5 % in 2008 to 77.8 
% in 2012. A detail summary is given (Table 2). 
 
The estimated annual increase was also higher 
for male patients and their associated CDL 
conditions. All age groups had their highest 
prevalence in 2012, except for age groups less 
than 12 and 12 to 50 years. Age group > 70 
years had the highest prevalence of patients in 
all the age groups for the study period in 2012 
with 29.3 % (n=78 879). The largest increase in 
the number of patients with at least one CDL 
condition were between 2008 and 2012 was for 
age group > 70 years (36.2 %; n = 20 985) and 
for chronic conditions (group > 70 years; 51.7 %; 
n=55 613). Age group > 70 years, thus had the 
highest estimated annual patient increase of 9 % 
(n=5 246) and estimated increase in number of 
CDL conditions of 12.9 % (n=13 903) (Table 3). 
 
Of all the CDL conditions, hypertension had the 
highest contribution during each of the study 
years followed by hyperlipidaemia. All 26 
conditions, had a patient increase of 139 336 
with an estimated annual increase of 34 834. The 
total number of patients increased by 41.3 % (n = 
139 336) between 2008 and 2012 with an 
estimated annual increase of 10.3 % (n = 34 
834). All CDL conditions except bronchiectasis 
had an overall increase in the number of patients 
from 2008 until 2012, hypertension had the 
highest increase (n = 49 531), followed by 
hyperlipidaemia (n = 35 490) and diabetes 
mellitus type 2 (n = 17 120). Bronchiectasis had 
an overall decrease between 2008 and 2012 of 
38 patients. The prevalence included patients 
with a single CDL condition or in combination 
with other CDL conditions. Diabetes insipidus 
had the lowest patient increase (n = 3) between 
2008 and 2012 (Table 4). 
 
Changes in the number of CDL conditions, 
adjusted for influence of age and gender 
 
An increase of 0.20 in chronic diseases was 
observed since 2008-2012 in patients having any 
CDL condition with an average of 1.57 (2008) co-
morbid CDL conditions to 1.77 in 2012. This 
difference in increase in average number of CDL 
conditions per patient between 2008 and 2012 
was of statistical significance (p < 0.05), but no 
large practical significance (d<0.8) (Table 5). 
 
All of the CDL conditions had increases in the 
average number of co-morbid CDL conditions 
per patient: however, glaucoma, haemophilia B 
and bronchiectasis were the only CDL conditions 
with an increase in co-morbid CDL conditions per 
patient of large practical significance (d>0.8). 
Asthma (increased by 0.18 co-morbid CDL 
conditions), hyperlipidaemia (increased by 0.20), 
hypertension (increased by 0.16), hypothyroidism 
(increased by 0.67) and diabetes mellitus type 2 
(increased by 0.24). Addison’s disease 
(increased by 0.23), coronary artery disease 
(increased by 0.25), cardiac failure (increased by 
0.14), multiple sclerosis (increased by 0.92), 
Parkinson’s disease (increased by 0.25) and 
chronic obstructive pulmonary disease increased 
by 0.17 CDL conditions per patient between 
2008 and 2012. The CDL condition with the 
smallest increase in CDL conditions per patient 
was for schizophrenia with 0.08 and the highest 
increase for patients with bronchiectasis with 
1.07 CDL conditions per patient. 
 
Epilepsy, glaucoma, haemophilia A and 
haemophilia B had increases of 0.17, 0.15, 0.29 
and 0.50 respectively between 2008 and 2012. 
The only CDL condition with an overall decrease 
of 0.21 in average number of CDL conditions 
was chronic renal disease. The CDL condition 
with the highest number of co-morbid CDL 
conditions was chronic renal disease with 3.54 in 
2008 to 3.37 in 2011. Cardiomyopathy had the 
highest average number of CDL conditions per 
patient during 2012 with 3.36. Average number 
of co-morbidities with hypothyroidism had an 





Chronic Diseases List conditions play a vital role 
in the consumption of health resources, not only 
due to the number of patients increasing but also 
the financial impact on medical schemes, 
patients and other resources. The present study 
reported continuous increase of total number of 
patients with at least one CDL over time. This 
might be attributed to chronic disease related 
lifestyle risk factors, increased registration of 
CDL conditions by medical scheme beneficiaries 
and increase in the number of medical scheme  
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Table 2: Prevalence of patients with at least one CDl condition according to the total number of patients on the database 
 
Description 2008 2009 2010 2011 2012 
Total number of 
patients 
 On the database (n) 
  
Gender Female 538 254 712 305 661 007 578 593 545 068 Male 436 243 595 223 559 282 499 237 484 627 
Age Group 
(Years) 
> 12 124 440 192 387 175 664 156 805  146 296 
≤ 12 - > 50 524 962 705 064 640 480 557 250 523 587 
≤ 50 - > 60 154 659 191 661 182 559 160 018 156 430 
≤ 60 - > 70 89 570 115 114 114 697 102 425 102 047 
≤ 70 80 866 103 302 106 889 101 336 101 339 
Total  974 497 1 307 528 1 220 289 1 077 834 1 029 699 
Total number of 
patients 
With at least one CDL 
Condition (n) 
Gender Female 125 548 (23.3 %) 142 690 (20 %) 140 133 (21.2 %) 129 192 (22.3 %) 146 678 (26.9 %) Male 88 731 (20.3%) 112 244 (18.8 %) 111 062 (19.8 %) 104 159 (20.8 %) 122 007 (25.1 %) 
Age Group 
(Years) 
> 12 3 611 (2.9 %) 4511 (2.3 %) 2 273 (2.4 %) 4165 (2.6 %) 4 088 (2.7 %) 
≤ 12 - > 50 49 519 (9.4 %) 60 697 (8.6 %) 57 516 (8.9 %) 52 628 (2.6 %) 56 479 (10.7%) 
≤ 50 - > 60 52 040 (33.6 %) 61 735 (32.2 %) 60 167 (32.9 %) 54 364 (9.4 %) 62 851 (40.1%) 
≤ 60 - > 70 51 215 (57.1 %) 60 026 (52.1 %) 59 716 (52%) 54 988 (33.9 %) 66 388 (65 %) 
≤ 70 57 894 (71.5 %) 67 965 (65.7 %) 69 523 (65 %) 67 206 (53.6 %) 78 879 (77.8 %) 
Total  214 279 (21.9 %) 254 934 (19.4 %) 251 195 (20.5 %) 233 351 (21.6 %) 268 685 (26 %) 
Total number of items 
on the database (n) 
Gender Female 9 893 928 12 834 715 12 103 038 * 10 327 159 * 9 237 012 * Male 6 545 325 8 814 276 8 424 739 * 7 439 420 * 7 172 238 * 
Age Group 
(Years) 
> 12 1 085 511 1 727 830 1 552 825 1 303 782 1 209 684 
≤ 12 - > 50 6 416 499 8 347 338 7 604 671 6 378 677 5 906 537 
≤ 50 - > 60 3 288 346 4 153 722 3 945 088 3 384 147 3 280 626 
≤ 60 - > 70 2 585 064 3 418 324 3 366 712 2 945 546 2 876 437 
≤ 70 3 063 833 4 001 777 4 058 470 3 754 442 3 136 008 
Total  16 439 253 21 648 991 20 527 766 17 766 594 16 409 292 
Total number of CDL 
conditions items (n) 
Gender 
Female 1 376 575 (13.9 %) 1 804 555 (14 %) 1 728 965 (14.9 %) 
1 735 386 (16.8 
%) 
1 551 209 (16.7 
%) 
Male 1 174 733 (17.9 %) 1 526 551 (17.3 %) 1 480 315 (17.5 %) 
1 515 603 (20.3 
%) 




> 12 20 380 (1.8 %) 43 014 (2.4 %) 39 469 (2.5 %) 40 356 (3 %) 34 964 (2.8 %) 
≤ 12 - > 50 445 947 (6.9 %) 578 377 (6.9 %) 541 606 (7.1 %) 554 426 (8.6 %) 520 912 (8.8 %) 
≤ 50 - > 60 589 949 (17.9 %) 746 537 (17.9 %) 710 961 (18 %) 712 964 (21 %) 712 071 (21.7 %) 
≤ 60 - > 70 646 249 (25 %) 837 411 (24.5 %) 807 093 (23.9 %) 817 432 (27.7 %) 822 188 (28.5%) 
≤ 70 848 783 (27 %) 1 125 767 (28.1 %) 1 110 151 (27.3 %) 
1 124 811 (29.9 
%) 974 985 (31 %) 
Total  2 551 308 (15.5 %) 3 331 106 (15.3 %) 3 209 280 (15.6 %) 
3 249 989 (18.2 
%) 
3 065 120 (18.6 
%) 
Note: All percentages are expressed as a percentage of the equivalent group on the total database.*  (2010)- Unidentified patients (n=11; R1 045.66), (2011)- Unidentified 
patients (n=15; R316.05), (2012- Unidentified patients (n=42;  R1 334.97) 
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Table 3: Change in number of patients with at least one CDL condition and the total number of CDL conditions, stratified according to age and gender 
 
Description 
2008 2012 Patient change             
(2008 vs 2012)              
(n) 
Chronic disease 
change  (2008 vs 
2012)                       
(n) 
Estimated annual 















Gender Female 125 548 193 182 146 678 258 263 ↑ 21 130 (16.8%)  ↑ 65 081 (33.6%) ↑ 5 283 (4.2%) ↑ 16 270 (8.4%) 
  Male 88 731 144 200 122 007 218 455 ↑ 33 276 (37.5%)  ↑ 74 255 (51.4%) ↑ 8 319 (9.3%) ↑ 18 564 (12.8%) 
Age Group 
(Years) 
> 12 3 611 3 654 4 088 4 137 ↑ 477 (13.2%)  ↑ 483 (13.2%) ↑ 119 (3.3%) ↑ 121 (3.3%) 
≤ 12 - > 50 49 519 63 090 56 479 77 362 ↑ 6 960 (14%)  ↑ 14 272 (22.6%) ↑ 1 740 (3.5%) ↑ 3 568 (5.6%) 
≤ 50 - > 60 52 040 77 881 62 851 105 427  ↑ 10 811 (17.2%) ↑  27 546 (35.3%) ↑ 2 703 (4.3%) ↑ 6 887 (8.8%) 
≤ 60 - > 70 51 215 85 375 66 388 126 797 ↑ 15 173 (29.6%) ↑  41 422 (48.5%) ↑ 3 793 (7.4%) ↑ 10 356 (12.1%) 
≤ 70 57 894 107 382 78 879 162 995 ↑ 20 985 (36.2%) ↑  55 613 (51.7%) ↑ 5 246 (9%) ↑ 13 903 (12.9%) 
 
Table 4: Prevalence of patients with all individual CDL conditions per condition 
 
CHRONIC DISEASE 

















Hypertension 57 627 44.4 70 058 50.1 69 193 50.7 62 909 50.9 69 248 50.8 
↑ 11 621 
(20.1%) ↑ 2 905 (5%) 
Hypothyroidism 24 558 18.9 11 824 8.4 11 899 8.7 10 658 8.6 11 724 8.6 
↓ 12 834 
(52.2%) 
↓ 3 209 
(13%) 
Hyperlipidaemia 15 239 11.7 18 385 13.1 17 778 13 15 002 12.1 18 216 13.3 
↑ 2 977 
(12.1%) ↑ 744 (3%) 
Asthma 12 139 9.3 14 559 10.4 14 107 10.3 13 586 10.9 13 803 10.1 
↑ 1 664 
(13.7%) ↑ 416 (3.4%) 
Diabetes Mellitus Type 2 6 158 4.74 7 425 5.3 7 097 5.2 6 393 5.1 7 133 5.2 
↑ 975 
(15.8%) ↑ 244 (3.9%) 
Epilepsy 3 770 2.9 4 991 3.5 4 635 3.4 4 101 3.3 4 665 3.4 
↑ 895 
(23.7%) ↑ 224 (5.9%) 
Diabetes Mellitus Type 1 2 912 2.2 2 199 1.5 1 744 1.2 1 952 1.5 1 656 1.2 




Glaucoma 1 622 1.2 1 967 1.4 1 987 1.4 1 817 1.4 2 185 1.6 
↑ 563 
(34.7%) ↑ 141 (8.6%) 
Cardiac failure 1 271 0.9 2 402 1.7 2 277 1.6 1 861 1.5 2 227 1.6 
↑ 956 
(75.2%) 
 ↑ 239 
(18.8%) 
Rheumatoid arthritis 872 0.6 1 109 0.7 1 108 0.8 1 042 0.8 1 257 0.9 
↑ 385 
(44.1%) ↑ 96 (11%) 
Dysthyrthmia 759 0.5 902 0.6 900 0.6 809 0.6 846 0.6 ↑ 87 (11.4%) ↑ 22 (2.8%) 
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Cardiomyopathy 606 0.4 474 0.3 416 0.3 349 0.2 270 0.2 
↓ 336 
(55.4%) 
 ↓ 84 
(13.8%) 
Coronary artery disease 588 0.4 781 0.5 641 0.4 991 0.8 562 0.3 ↓ 26 (4.4%) ↓ 7 (1.1%) 
Parkinson's disease 531 0.4 645 0.4 642 0.4 568 0.4 598 0.4 ↑ 67 (12.6%) ↑ 17 (3.1%) 
Chronic obstructive pulmonary 
disease 421 0.3 578 0.4 538 0.3 451 0.3 504 0.3 ↑ 83 (19.7%) ↑ 21 (4.9%) 
Crohn's disease 100 0.0 239 0.1 232 0.1 218 0.1 237 0.1 ↑ 137 (137%) 
 ↑ 34 
(34.2%) 
Multiple sclerosis 63 0.05 315 0.2 293 0.22 198 0.16 171 0.13 
↑ 108 
(171.4%) 
 ↑ 27 
(42.8%) 
Ulcerative colitis 42 0.03 92 0.07 77 0.06 71 0.06 84 0.06 ↑ 42 (100%)  ↑ 11 (25%) 
Addison's disease 40 0.03 42 0.03 36 0.03 37 0.03 38 0.03 ↓ 2 (5%)  ↓ 1 (1.2%) 
Systemic lupus erythematosus 38 0.03 51 0.04 59 0.04 49 0.04 65 0.05 ↑ 27 (71%)  ↑ 7 (17.7%) 
Bronchiectasis 36 0.03 36 0.03 30 0.02 21 0.02 4 0.00 ↓ 32 (88.8%) ↓ 8 (22.2%) 
Haemophilia A 20 0.02 27 0.02 31 0.02 35 0.03 30 0.02 ↑ 10 (50%)  ↑ 3 (12.5%) 
Diabetes insipidus 10 0.01 7 0.01 10 0.01 8 0.01 8 0.01 ↓ 2 (20%)  ↓ 1 (5%) 
Chronic renal disease 9 0.01 36 0.03 33 0.02 29 0.02 82 0.06 
↑ 73 
(811.1%) 
 ↑ 18 
(202.7%) 
Haemophilia B 1 0.00 1 0.00 1 0.00 1 0.00 2 0.00 ↑ 1 (100%) ↑ 1 (25%) 
Total 129 799 100.00 139 634 100.00 136 224 100.00 123 580 100.00 136 097 100.00 
↑ 6 298 
(4.8%) 
↑ 1 575 
(1.2%) 
 














e interval          










1 222 444 






2009 1.68 0.00 1.67-1.68 
2010 1.69 0.00 1.68-1.69 
2011 1.72 0.00 1.71-1.72 
2012 1.77 0.00 1.77-1.78 
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beneficiaries as reported by the pharmaceutical 
benefit company used in this study. Similar 
increased burden of disease associated with 
chronic conditions was reported by a study 
conducted in twenty three different countries [8]. 
 
The current study reported higher prevalence of 
CDL conditions in female patients as compared 
to male patients since 2008 to 2012. Higher 
prevalence of non-communicable disease in 
females was also reported by other studies 
conducted in South Africa and Germany[9,10]. 
Findings from another study conducted in United 
States reported higher prevalence of co-morbid 
chronic conditions in females as compared to 
males [11]. 
 
The present study found an increase in CDL 
conditions proportionate to increase in age. This 
might be due to the fact that people live longer 
than before. According to a survey, one in twenty 
people were aged 65 years and older a century 
ago, however, the proportion was one in six in 
2011 and it has been estimated that by 2050, the 
proportion will be one in four with chronic 
disease. This situation will lead to an increase 
risk of CDL conditions such as hypertension, 
hyperlipidaemia and diabetes associated with 
aging [8]. The results of conducted in the United 
States showed that prevalence of co-morbid 
chronic conditions increase with increase in age. 
Higher prevalence of non-communicable 
diseases in elderly was also reported by another 
study conducted in South Africa [12]. 
 
It has been estimated that deaths associated 
with all chronic diseases globally, may increase 
from 61 % of the total disease burden in 2005 to 
71 % in 2030.On the other hand, deaths from 
cardiovascular disease and chronic respiratory 
disease may increase from 33 to 36 % and 8 to 
12 % of the total disease burden by 2030 [8]. The 
findings of the current study revealed that 
chances of co-morbidities in individual patients 
with a CDL condition are high. Chronic renal 
disease was the only CDL condition with patients 
having an overall decrease in co-morbidity, 
although the average was still higher than the 
other conditions over the majority of the study 
period. This higher co-morbidity prevalence 
might be due to associated risk factors, such as 
hypertension, diabetes mellitus type 2 and 
obesity.  
 
The high average number of co-morbid CDL 
conditions for coronary artery disease, may be 
attributed to diabetes mellitus type 2 and 
hyperlipidaemia, as being most commonly 
prevalent CDL condition [13].The present study 
reported hypertension and hyperlipidaemia 
among the top three most prevalent chronic 
diseases. These results are in line with similar 
findings from another study conducted in South 
Africa [14]. Another study conducted in United 
States confirmed hypertension and 
hyperlipidaemia currently as the most prevalent 
chronic diseases [15].The increase in burden of 
chronic diseases will result in use of complex 
drug regimens which in turn will not only increase 
cost of therapy but will also promote issues 
related to unwanted side effects, drug-drug 
interactions, resistance and patient non-
compliance.  
 
Limitations of the study 
 
The results of the study are based on the data 
from the medicine claims database of a 
nationally (South African) representative PBM 





The prevalence of patients with CDL conditions 
along with risk of co-morbidity has been 
increasing with time in private healthcare sector 
of South Africa. Individual patients with any of the 
CDL conditions acquired on average at least one 
additional CDL co-morbidity (except for chronic 
renal disease), especially, when other CDL 
conditions were known as risk factors. Risk of 
increase co-morbidities with age and among 
different genders was prevalent. The current 
situation will easily overwhelm healthcare system 
as awareness regarding the magnitude and 
consequences of increased chronic disease 
burden as well as the capacity to respond 
appropriately with cost-effective measures is still 
low. Thus, this calls for more extensive research 
to recognise and accommodate the impact of the 
increased chronic disease burden to address this 
public health concern appropriately, especially in 
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